SOD1 and amyotrophic lateral sclerosis: Still, because repurposing remains an expeditious path toward development of therapeutics for people living with ALS, we have tested dozens of FDA approved therapeutics in the B6SJL(G93A-SOD1)/Gur1 model of ALS (hereafter referred to as G93A-SOD1 mice) to evaluate their potential as clinical candidates with limited success [4, 5, 6, 7].